Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.

Yan Yin, Nora T. Kizer, Premal H. Thaker, Katherine B. Chiappinelli, Kathryn M. Trinkaus, Paul J. Goodfellow, Liang Ma

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Alternative strategies beyond current chemotherapy and radiation therapy regimens are needed in the treatment of advanced stage and recurrent endometrial cancers. There is considerable promise for biologic agents targeting the extracellular signal-regulated kinase (ERK) pathway for treatment of these cancers. Many downstream substrates of the ERK signaling pathway, such as glycogen synthase kinase 3β (GSK3β), and their roles in endometrial carcinogenesis have not yet been investigated. In this study, we tested the importance of GSK3β inhibition in endometrial cancer cell lines and in vivo models. Inhibition of GSK3β by either lithium chloride (LiCl) or specific GSK3β inhibitor VIII showed cytostatic and cytotoxic effects on multiple endometrial cancer cell lines, with little effect on the immortalized normal endometrial cell line. Flow cytometry and immunofluorescence revealed a G2/M cell cycle arrest in both type I (AN3CA, KLE, and RL952) and type II (ARK1) endometrial cancer cell lines. In addition, LiCl pre-treatment sensitized AN3CA cells to the chemotherapy agent paclitaxel. Administration of LiCl to AN3CA tumor-bearing mice resulted in partial or complete regression of some tumors. Thus, GSK3β activity is associated with endometrial cancer tumorigenesis and its pharmacologic inhibition reduces cell proliferation and tumor growth.

Original languageEnglish
Pages (from-to)16617-16637
Number of pages21
JournalInternational journal of molecular sciences
Issue number8
StatePublished - 2013


Dive into the research topics of 'Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.'. Together they form a unique fingerprint.

Cite this